Request Demo

Last update 08 May 2025

CD-30 positive pleomorphic large T-cell cutaneous lymphoma

Last update 08 May 2025

Basic Info

Synonyms

CD-30 positive pleomorphic large T-cell cutaneous lymphoma, CD-30 positive pleomorphic large T-cell cutaneous lymphoma (disorder), CD30+ pleomorphic large T-cell cutaneous lymphoma

+ [1]

Introduction-

Drugs associated with CD-30 positive pleomorphic large T-cell cutaneous lymphoma

Brentuximab Vedotin

Target

CD30 x Tubulin

Mechanism

CD30 inhibitors [+1]

Active Org.

Seagen, Inc. [+8]

Originator Org.

Seagen, Inc.

Active Indication

Diffuse Large B-Cell Lymphoma [+40]

Inactive Indication

Acute Lymphoblastic Leukemia [+49]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date19 Aug 2011

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells(Medical College of Wisconsin)

Target

CD3 x CD30

Mechanism

CD3 stimulants [+1]

Active Org.

Medical College of Wisconsin

Originator Org.

Medical College of Wisconsin

Active Indication

Anaplastic Large-Cell Lymphoma [+4]

Inactive Indication-

Drug Highest PhasePhase 1/2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with CD-30 positive pleomorphic large T-cell cutaneous lymphoma

NCT05544968

/ Not yet recruitingPhase 1/2IIT

Phase I Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-armed Anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).

Start Date01 Jun 2025

Sponsor / Collaborator

Medical College of Wisconsin

NCT01352520

/ Active, not recruitingPhase 2IIT

Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)

The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.

Start Date01 Jun 2011

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with CD-30 positive pleomorphic large T-cell cutaneous lymphoma

100 Translational Medicine associated with CD-30 positive pleomorphic large T-cell cutaneous lymphoma

0 Patents (Medical) associated with CD-30 positive pleomorphic large T-cell cutaneous lymphoma

Literatures (Medical) associated with CD-30 positive pleomorphic large T-cell cutaneous lymphoma

01 Jun 2018·Annales de Dermatologie et de VénéréologieQ4 · MEDICINE

Lymphoprolifération cutanée primitive CD30+ sous fingolimod : un cas et revue systématique de la littérature

Q4 · MEDICINE

Review

Author: Francès, C ; Senet, P ; Duriez, P ; Moguelet, P ; Chasset, F ; Cesbron, E ; Barbaud, A ; Monfort, J-B ; Giannesini, C

BACKGROUNDFingolimod is an oral immunomodulator approved for relapsing-remitting multiple sclerosis. We report a case of a primary cutaneous CD30+ T-cell lymphoproliferation occurring 6 months after initiation of fingolimod. Based on a systematic literature review, the characteristics of these fingolimod-induced lymphoproliferative disorders are described.PATIENTS AND METHODSA 56-year-old woman developed cutaneous indurated and ulcerated nodular lesions 6 months after starting fingolimod for active relapsing-remitting multiple sclerosis. Histological examination of a punch biopsy sample demonstrated a polymorphous dermal infiltrate containing large atypical CD30+ cells, leading to diagnosis of primary cutaneous CD30+ anaplastic large-cell lymphoma. Chest-abdomen-pelvis CT scans were performed to rule out secondary cutaneous anaplastic large-cell lymphoma. Spontaneous clinical regression was observed and after assessing the benefit/risk ratio, it was decided to continue fingolimod under strict surveillance, with no relapse occurring by month 18.DISCUSSIONA systematic review of PUBMED/Medline and Embase identified seven other cases of lymphoproliferative disorders occurring during fingolimod treatment, including two other cases of primitive cutaneous CD30+ lymphoproliferative disorders.CONCLUSIONEven if cutaneous CD30+ lymphoproliferative disorders occur only rarely during fingolimod treatment, dermatologists should nevertheless be aware of this association for which strict dermatological surveillance is required. We would also stress that these CD30+ lymphoproliferative disorders can disappear spontaneously, as in our case, even if treatment by fingolimod is continued.

01 Jul 2016·Aesthetic Surgery JournalQ2 · MEDICINE

Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Q2 · MEDICINE

Article

Author: Epstein, Alan L ; Brody, Garry S ; MacLeod, Roderick A F ; Adams, William P ; Morgan, John ; Khare, Pranay ; Xu, Haiying ; Deva, Anand ; Van Natta, Bruce W ; Kadin, Marshall E

Almost 200 women worldwide have been diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The unique location and specific lymphoma type strongly suggest an etio-pathologic link between breast implants and BIA-ALCL. It is postulated that chronic inflammation via bacterial infection may be an etiological factor. BIA-ALCL resembles primary cutaneous ALCL (pcALCL) in morphology, activated T-cell phenotype, and indolent clinical course. Gene expression array analysis, flow cytometry, and immunohistochemistry were used to study pcALCL and BIA-ALCL cell lines. Clinical samples were also studied to characterize transcription factor and cytokine profiles of tumor cells and surrounding lymphocytes. BIA-ALCL and pcALCL were found to have common expression of transcription factors SOCS3, JunB, SATB1, and a cytokine profile suggestive of a Th1 phenotype. Similar patterns were observed in a CD30+ cutaneous lymphoproliferative disorder (LPD). The patterns of cytokine and transcription factor expression suggest that BIA-ALCL is likely to arise from chronic bacterial antigen stimulation of T-cells. Further analysis of cytokine and transcription factor profiles may allow early detection and treatment of BIA-ALCL leading to better prognosis and survival. LEVEL OF EVIDENCE 5: Risk.

01 Dec 2015·International Journal of Surgical PathologyQ4 · MEDICINE

Mucosal CD30-Positive T-Cell Lymphoproliferative Disorder Arising in the Oral Cavity Following Dental Implants

Q4 · MEDICINE

Article

Author: Choe, Ji-Young ; Jeon, Yoon Kyung ; Yoon, Hye-Jung

Mucosal CD30-positive T-cell lymphoproliferative disorder (CD30+ T-cell LPD) is a novel entity with unique clinicopathological features and an indolent behavior. Here we report the first case of mucosal CD30+ T-cell LPD arising in the oral cavity following dental implant. A 70-year-old woman presented with swelling and redness of the oral mucosa of right maxilla and left mandible surrounding dental implants that had been placed 8 years previously. Radiological examination revealed enhancing oral lesions and multiple cervical lymph nodes. Microscopic examination showed diffuse infiltration of large anaplastic cells with characteristic morphology of hallmark cells described in anaplastic large cell lymphoma. These cells were diffusely positive for CD30, CD3, CD4, CD2, CD5, CD7, TIA-1, and TCRβF1, but negative for CD20, CD8, CD45, EMA, ALK, and Epstein-Barr virus. T-cell monoclonality was detected in a TCRγ gene rearrangement study. This a unique case of mucosal CD30+ T-cell LPD with unusual presentation following dental implant.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CD-30 positive pleomorphic large T-cell cutaneous lymphoma

Basic Info

Related

Analysis